Author

Boldizsár Jójárt

CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE
CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE

Boldizsár Jójárt  et al.

LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE
LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE

Boldizsár Jójárt  et al.

POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES

Boldizsár Jójárt  et al.

INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE
INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE

Boldizsár Jójárt  et al.

INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE
INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE

POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

Boldizsár Jójárt  et al.

CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS
CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS

Boldizsár Jójárt  et al.

PLASMINOGEN ACTIVATOR INHIBITOR 1 A POTENTIAL NEW THERAPEUTIC TARGET IN THE TREATMENT OF CHRONIC PANCREATITIS
PLASMINOGEN ACTIVATOR INHIBITOR 1 A POTENTIAL NEW THERAPEUTIC TARGET IN THE TREATMENT OF CHRONIC PANCREATITIS

Boldizsár Jójárt  et al.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE
SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Boldizsár Jójárt  et al.

INHIBITION OF ORAI1 PROTECTS THE PANCREATIC TISSUE AND REDUCES THE PROGRESSION OF FIBROSIS IN CHRONIC PANCREATITIS
INHIBITION OF ORAI1 PROTECTS THE PANCREATIC TISSUE AND REDUCES THE PROGRESSION OF FIBROSIS IN CHRONIC PANCREATITIS

Boldizsár Jójárt  et al.

INTERPLAY OF ORAI1 CA2+ CHANNEL AND CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) IN EPITHELIAL PHYSIOLOGY
INTERPLAY OF ORAI1 CA2+ CHANNEL AND CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) IN EPITHELIAL PHYSIOLOGY

Boldizsár Jójárt  et al.

ORAI1 CALCIUM CHANNEL INHIBITION PREVENTS PROGRESSION OF RECURRENT ACUTE AND CHRONIC PANCREATITIS
ORAI1 CALCIUM CHANNEL INHIBITION PREVENTS PROGRESSION OF RECURRENT ACUTE AND CHRONIC PANCREATITIS

Boldizsár Jójárt  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

Boldizsár Jójárt  et al.

Item 1 - 14 / 14
1